Simplify Asset Management Inc. Makes New $1.97 Million Investment in Oculis Holding AG $OCS

Simplify Asset Management Inc. purchased a new position in shares of Oculis Holding AG (NASDAQ:OCS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 98,765 shares of the company’s stock, valued at approximately $1,972,000. Simplify Asset Management Inc. owned 0.19% of Oculis at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Gildi lifeyrissjodur acquired a new stake in Oculis in the fourth quarter valued at approximately $50,250,000. Aberdeen Group plc raised its holdings in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after acquiring an additional 493,827 shares in the last quarter. Syquant Capital Sas acquired a new stake in Oculis in the fourth quarter valued at approximately $3,849,000. China Universal Asset Management Co. Ltd. raised its holdings in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Analyst Upgrades and Downgrades

OCS has been the topic of several analyst reports. Needham & Company LLC raised their target price on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. HC Wainwright raised their target price on shares of Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Guggenheim started coverage on Oculis in a research report on Wednesday. They set a “buy” rating and a $75.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.38.

Oculis Stock Performance

NASDAQ:OCS opened at $29.49 on Monday. The stock has a 50-day simple moving average of $27.48 and a 200-day simple moving average of $24.90. The stock has a market cap of $1.71 billion, a P/E ratio of -13.85 and a beta of 0.38. Oculis Holding AG has a 1 year low of $16.00 and a 1 year high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. As a group, analysts anticipate that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.